Definitive Contract 75N95021C00017
Award Date
8/11/21
Potential Completion Date
9/29/23
Potential Value
$242K
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10019, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $249,750.00 firm fixed-price definitive contract awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells, and expanding and validating neural progenitor cells from patients with conditions such as Alzheimer's...
This is a $15,375 firm-fixed-price purchase order contract awarded by the National Human Genome Research Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation, Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines from patients with Alzheimer's disease and related dementias, differentiating stem cells into insulin-producing beta cells,...
This federal contract award from the National Human Genome Research Institute, an agency within the U.S. Department of Health and Human Services, was made to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract, valued at $425,000.00, is for the generation of 50 induced pluripotent stem cell (iPSC) lines from fusion study fibroblast cell lines. No set-aside designation was used for this contract. The New York Stem Cell Foundation Inc....
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $150,000.00 firm fixed-price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization that conducts stem cell research. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells into insulin-producing beta cells, and expanding and validating neural...
The National Institute of Drug Abuse awarded a $414,000 firm fixed price definitive contract to New York Stem Cell Foundation Inc. to provide expansion, differentiation, and validation of 36 neural progenitor cell lines derived from induced pluripotent stem cells obtained from subjects with psychiatric conditions. The original solicitation sought proposals to outsource these services within specified timeframes, with an emphasis on technical approach. New York Stem Cell Foundation will...
This is a $361,950 firm fixed-price purchase order awarded by the National Human Genome Research Institute (NHGRI), a civilian agency within the National Institutes of Health (NIH), to the New York Stem Cell Foundation Inc., a non-profit organization and foundation. The contract is for the generation of induced pluripotent stem cells (iPSCs) and the differentiation of beta cells. The work will be performed in Bethesda, Maryland, and the contract has an ultimate completion date of September 24,...
This $238,000.00 firm-fixed price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to the New York Stem Cell Foundation, Inc., a non-profit organization that conducts stem cell research. The contract is for the derivation of induced pluripotent stem cells, which aligns with the foundation's work in generating stem cell lines, differentiating them into various cell types, and...
The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a $105,000 firm fixed price purchase order to New York Stem Cell Foundation Inc. as the prime contractor. The contract is to support the agency's research efforts and will be performed in New York, New York over a one year period from September 2023 through September 2024. No major subcontractors or set aside designations were indicated. The National Institute on Drug Abuse...
This is a $1,405,000.00 firm fixed price purchase order contract awarded by the National Human Genome Research Institute, a component of the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to beta cell differentiation and cell assays, which aligns with the original solicitation that sought the development of assays to evaluate the differentiation of stem cells into insulin-producing beta cells. No...
This is a $1,399,499.93 firm fixed-price definitive contract awarded by the National Eye Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The purpose of this contract is to obtain induced pluripotent stem cells (iPSCs) to advance the study of the functional basis of genetic variants associated with age-related macular degeneration (AMD). No set-aside designation was used for this award. The...